Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Biochim Biophys Acta ; 1403(1): 97-101, 1998 May 27.
Article in English | MEDLINE | ID: mdl-9622602
2.
Cardiovasc Res ; 39(2): 475-84, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9798532

ABSTRACT

OBJECTIVE: Fibrinogen is an independent risk factor for cardiovascular disease. This study has investigated the role of intracellular Ca2+ ([Ca2+]i) and tyrosine phosphorylation in the attachment of human and rat-derived cultured vascular smooth muscle cells to fibrinogen. METHODS: Cells were cultured from human saphenous vein segments (HVSMC) and from an established rat aortic cell line (A7r5). [Ca2+]i was measured using fura-2 and adhesion was studied using pre-coated 96 well polystyrene plates. RESULTS: Fibrinogen increased [Ca2+]i in both cell types. In A7r5 cells fibrinogen-induced increases in [Ca2+]i were partially inhibited by a peptide containing the amino acid sequence Arg-Gly-Asp (RGD) which interferes with binding to integrins. In contrast RGD increased [Ca2+]i in HVSMC, but did not inhibit responses to fibrinogen. Ni2+, an inorganic calcium channel blocker largely abolished the rise in [Ca2+]i, but blockers of voltage-operated calcium channels failed to affect [Ca2+]i responses to fibrinogen in either cell type. Genistein, an inhibitor of tyrosine kinase inhibited fibrinogen-induced rises in [Ca2+]i, while daidzein, an inactive analogue, was without effect. Adhesion of cells to fibrinogen was concentration- and time-dependent. Cell adhesion to fibrinogen was partially inhibited by RGD peptide in both cell types. Adhesion of cell to fibrinogen was inhibited by chelation of [Ca2+]i with BAPTA-AM, inhibition of Ca2+ entry by Ni2+, and inhibition of tyrosine kinases by genistein, but heparin had no effect on adhesion. CONCLUSIONS: Vascular smooth muscle cells attach to fibrinogen in part through RGD-type interactions. Activation of tyrosine kinase(s) and a subsequent rise in [Ca2+]i appear to be important signals mediating the response to fibrinogen.


Subject(s)
Calcium/metabolism , Fibrinogen/pharmacology , Intracellular Fluid/metabolism , Muscle, Smooth, Vascular/physiology , Tyrosine/metabolism , Animals , Calcium Channel Blockers/pharmacology , Cell Adhesion/drug effects , Cell Line , Cells, Cultured , Chelating Agents/pharmacology , Egtazic Acid/analogs & derivatives , Egtazic Acid/pharmacology , Enzyme Inhibitors/pharmacology , Fibrinogen/physiology , Genistein/pharmacology , Humans , Integrins/metabolism , Muscle, Smooth, Vascular/drug effects , Nickel/pharmacology , Oligopeptides/pharmacology , Phosphorylation , Protein-Tyrosine Kinases/antagonists & inhibitors , Rats , Regression Analysis
3.
J Hypertens ; 12(2): 129-35, 1994 Feb.
Article in English | MEDLINE | ID: mdl-8021463

ABSTRACT

OBJECTIVE: To examine the changes in the rate of DNA synthesis in the aorta and mesenteric and subcutaneous resistance arteries during the development of renovascular hypertension. METHODS: Goldblatt two-kidney, one clip hypertensive and sham-operated control rats were studied 3, 7, 14 and 28 days after surgery. DNA synthesis was measured as the hourly rate of [3H]-thymidine incorporation into the DNA. RESULTS: Three days after renal artery constriction there was a significant increase in the DNA synthesis in both the aorta and the mesenteric vessels, although the blood pressure was not changed. DNA synthesis was elevated during the development of hypertension, but returned to control levels after 28 days when the blood pressure had reached a plateau. By contrast, there was no increase of DNA synthesis in the subcutaneous vessels at any time after renal artery constriction. The plasma renin concentration also was increased after 3 days in the clipped rats and remained elevated throughout the study. There were no significant changes in the blood pressure, the plasma renin concentration or the rate of vascular DNA synthesis in the sham-operated control rats. CONCLUSIONS: These data indicate that there are regional differences in the vascular response to the induction of renovascular hypertension and that in some vascular beds an increase in DNA synthesis precedes the rise in blood pressure.


Subject(s)
Blood Vessels/metabolism , DNA/biosynthesis , Hypertension, Renovascular/etiology , Hypertension, Renovascular/metabolism , Animals , Aorta/metabolism , Arteries/metabolism , Female , In Vitro Techniques , Mesenteric Arteries/metabolism , Rats , Rats, Wistar , Renin/blood , Thymidine/metabolism
4.
Br J Pharmacol ; 129(7): 1347-54, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10742290

ABSTRACT

1. Tyrosine kinases have been proposed as regulators of voltage-operated calcium channels. The effects of a range of structurally different inhibitors of protein tyrosine kinases (PTK) were examined on voltage-operated calcium channel currents (I(Ba)) and pp60(c-src) kinase (c-src) activity in vitro. 2. I(Ba) was measured in single myocytes isolated from rabbit ear artery by conventional whole cell voltage-clamp techniques. The activity of purified human c-src was measured in vitro using a non-radioactive assay. 3. Bath application of tyrphostin-23 and genistein (non-selective PTK inhibitors), bistyrphostin (a receptor-PTK-selective inhibitor) and PP1 (a src family-selective inhibitor) inhibited I(Ba) in a concentration-dependent manner over a range of test membrane potentials. Intracellular application of peptide-A, a peptide inhibitor of c-src also inhibited currents. Inhibitor potency series against I(Ba) was PP1 > genistein > tyrphostin 23 > bistyrphostin. 4. Tyrphostin-23, genistein, PP1, and peptide-A shifted the steady-state inactivation curves in a hyperpolarized direction without altering their slope. The inhibitors had no significant effects on I(Ba) activation calculated from current-voltage relationships. 5. The agents inhibited c-src activity in a concentration-dependent manner. The order of potency was PP1 > genistein > peptide-A > tyrphostin-23 > bistyrphostin. The IC(50) for inhibition of c-src activity was similar to the IC(50) for inhibition of I(Ba) in all cases. 6. Western blot analysis with a specific antibody to c-src showed the presence of this cytoplasmic tyrosine kinase in rabbit ear artery cells. 7. A range of structurally dissimilar inhibitors of PTKs inhibit I(Ba) and c-src activity with similar potency. These data provide further evidence implicating endogenous c-src in the modulation of L-type calcium channels in vascular smooth muscle cells.


Subject(s)
Calcium Channels/drug effects , Enzyme Inhibitors/pharmacology , Membrane Potentials/drug effects , Muscle, Smooth, Vascular/drug effects , Protein-Tyrosine Kinases/antagonists & inhibitors , Proto-Oncogene Proteins pp60(c-src)/drug effects , Animals , Arteries/cytology , Arteries/drug effects , Arteries/physiology , Calcium Channels/physiology , Dose-Response Relationship, Drug , Ear/blood supply , Electric Stimulation , Genistein/pharmacology , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/physiology , Proto-Oncogene Proteins pp60(c-src)/metabolism , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Rabbits , Tyrphostins/pharmacology , src-Family Kinases/antagonists & inhibitors
5.
Br J Pharmacol ; 124(2): 307-16, 1998 May.
Article in English | MEDLINE | ID: mdl-9641547

ABSTRACT

1. The effect of increasing cellular tyrosine phosphorylation by inhibiting endogenous tyrosine phosphatases was examined on voltage-operated calcium channel currents in vascular smooth muscle cells. 2. In single ear artery smooth muscle cells of the rabbit, studied by the whole cell voltage clamp technique, intracellular application of the tyrosine phosphatase inhibitors, sodium orthovanadate (100 microM) and peroxyvanadate (100 microM orthovanadate + 1 mM H2O2) increased voltage-operated calcium channel currents by 56% and 83%, respectively. 3. Bath application of two other membrane permeant tyrosine phosphatase inhibitors, phenylarsine oxide (100 microM) and dephostatin (50 microM) also increased voltage-operated calcium channel currents by 48% and 52%, respectively. 4. The selective tyrosine kinase inhibitor, tyrphostin-23 (100 microM) reduced calcium channel currents by 41%. Pre-incubation with tyrphostin-23 abolished the effects of peroxyvanadate, phenylarsine oxide and dephostatin on calcium channels. 5. Western blot analysis of rabbit ear artery cell lysates showed increased tyrosine phosphorylation of several endogenous proteins following treatment with peroxyvanadate. 6. These results indicate that a number of structurally dissimilar inhibitors of tyrosine phosphatases increase voltage-operated calcium channel currents in arterial smooth muscle cells presumably due to increased tyrosine phosphorylation.


Subject(s)
Calcium Channels/drug effects , Enzyme Inhibitors/pharmacology , Muscle, Smooth, Vascular/enzymology , Protein Tyrosine Phosphatases/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , Tyrphostins/pharmacology , Animals , Arsenicals/pharmacology , Arteries , Calcium Channels/physiology , Ear/blood supply , Electrophoresis, Polyacrylamide Gel , Hydrogen Peroxide , Hydroquinones/pharmacology , Muscle, Smooth, Vascular/drug effects , Patch-Clamp Techniques , Rabbits , Vanadates/pharmacology
6.
Br J Pharmacol ; 121(8): 1789-95, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9283719

ABSTRACT

1. In this study the effect of lovastatin, an inhibitor of cholesterol and isoprenoid synthesis, on the rises in intracellular calcium concentration ([Ca2+]i) induced by platelet derived growth factor BB (PDGF-BB), angiotensin II (AII), low density lipoproteins (LDL) and foetal calf serum (FCS) was examined in human cultured vascular smooth muscle cells (VSMC) from saphenous vein. Changes in [Ca2+]i were measured in cell suspensions by the Ca2+ sensitive probe, fura 2. 2. Incubation with lovastatin for 24-26 h markedly reduced the peak rise and sustained phase of [Ca2+]i elevation in response to PDGF-BB but the responses to AII, LDL and FCS were unaffected. Further experiments showed that lovastatin pretreatment inhibited PDGF-BB induced Ca2+ influx but not intracellular Ca2+ release. This inhibition could be overcome by co-incubation with mevalonic acid. 3. Pretreatment of cells with the heterotrimeric G protein inhibitor pertussis toxin for up to 24 h completely abolished AII-induced [Ca2+]i rises but the response to PDGF-BB was unaffected. 4. The tyrosine kinase inhibitor genistein largely abolished PDGF-BB-induced [Ca2+]i elevation but had no significant effect on AII-induced responses. 5. Pre-incubation with lovastatin had no effect on the level of tyrosine phosphorylation of PDGF-beta receptors (as measured by Western blot) in response to the PDGF-BB ligand. 6. PDGF-BB elicits Ca2+ influx via a tyrosine kinase-dependent mechanism distinct from the heterotrimeric G protein coupled pathway utilized by AII. Lovastatin most likely acts by inhibition of isoprenylation (via blockade of isoprenoid synthesis) of an intermediate molecule involved in PDGF-BB-induced Ca2+ influx.


Subject(s)
Calcium/metabolism , Enzyme Inhibitors/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Lovastatin/pharmacology , Mitogens/pharmacology , Muscle, Smooth, Vascular/metabolism , Cells, Cultured , Humans , Male , Muscle, Smooth, Vascular/cytology , Platelet-Derived Growth Factor/pharmacology , Protein-Tyrosine Kinases/physiology , Receptors, Platelet-Derived Growth Factor/analysis
7.
Biochem Biophys Res Commun ; 258(2): 425-30, 1999 May 10.
Article in English | MEDLINE | ID: mdl-10329403

ABSTRACT

The widely expressed phospholipase C gamma1 (PLCgamma1) isoform has been implicated in the signalling of cell growth through its ability to hydrolyse phosphatidylinositol 4,5-bisphosphate to give inositol 1,4,5-trisphosphate and 1,2-diacylglycerol. Stimulation of PLCgamma1 activity occurs upon phosphorylation of specific tyrosine residues, although it is unclear how this phosphorylation actually stimulates catalytic activity. Indeed recent reports suggest that accessory factors such as GTP-binding proteins may also be required for complete activation of PLCgamma1 in some cells. This may be of importance in vascular smooth muscle where traditionally G-protein linked PLCbeta isoforms are often absent. Here, we show that bovine aortic PLCgamma1 activity is substantially enhanced by both GTPgammaS and sodium fluoride. Similarly, immunoprecipitated PLCgamma1 is associated with an approximately 40kDa GTPgammaS-binding protein and both Galphai and Galphaq were detected in this immunoprecipitate. This data suggests that bovine aortic PLCgamma1 is both associated with, and may be activated by, heterotrimeric G-proteins.


Subject(s)
Aorta/enzymology , GTP-Binding Proteins/metabolism , Isoenzymes/metabolism , Type C Phospholipases/metabolism , Animals , Aorta/cytology , Biopolymers , Cattle , Cells, Cultured , Enzyme Activation , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Isoenzymes/isolation & purification , Phospholipase C gamma , Phosphorylation , Precipitin Tests , Protein Binding , Type C Phospholipases/isolation & purification , Tyrosine/metabolism
8.
Arterioscler Thromb Vasc Biol ; 17(11): 2622-9, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9409235

ABSTRACT

The effect of the three platelet-derived growth factor (PDGF) isoforms AA, AB, and BB on migration was investigated in cultured human saphenous vein smooth muscle cells. The modified Boyden chamber technique yielded efficacies BB >> AB, AA = 0. However, the BB concentration-response relationship displayed a pronounced peak, occurring between 1 and 10 ng/mL, with no response above this range. Checkerboard analysis showed that the promotion of migration at low concentrations was chemotactic in nature but that the downturn was independent of gradient. Furthermore, at high concentrations BB was able to prevent chemotaxis induced by fetal calf serum and epidermal growth factor (EGF). Experiments using low concentrations of BB in combination with high concentrations of AA to saturate PDGF alpha-receptors in the presence and absence of a neutralizing antibody to alpha-receptors revealed that alpha-receptor activation induced partial inhibition of chemotaxis but this did not account for the inhibition of migration by high concentrations of BB. Despite possessing no significant chemotactic action itself, high concentrations of the AB isoform completely inhibited BB induced chemotaxis. Taken together these results suggest that the chemotactic signal induced by PDGF is dominated by PDGF beta-receptors and switches from positive at low concentrations to negative at higher concentrations. Stimulation of DNA synthesis by the three isoforms (as measured by [3H] thymidine incorporation) yielded saturable responses for the AB and BB isoforms, with similar efficacy and weak or no response for the AA isoform. Concentration-dependent patterns of tyrosine phosphorylation of certain proteins mirrored the form of the chemotactic response and suggest one possible underlying regulatory mechanism to account for the disparity between PDGF-induced chemotaxis and DNA synthesis.


Subject(s)
Chemotaxis/drug effects , Muscle, Smooth, Vascular/drug effects , Platelet-Derived Growth Factor/pharmacology , Receptors, Platelet-Derived Growth Factor/physiology , Becaplermin , Cell Division/drug effects , Cells, Cultured , DNA Replication/drug effects , Depression, Chemical , Humans , Muscle, Smooth, Vascular/physiology , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects , Proto-Oncogene Proteins c-sis , Receptor, Platelet-Derived Growth Factor beta , Receptors, Platelet-Derived Growth Factor/drug effects , Saphenous Vein/cytology , Signal Transduction , Stimulation, Chemical
9.
Arterioscler Thromb Vasc Biol ; 17(10): 2107-14, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9351379

ABSTRACT

Thrombospondin-1 (TSP-1) is a matricellular protein that is present in negligible amounts in normal human vasculature but occurs in significant amounts in diseased vessels. In this study, we examined the effect of TSP-1 on DNA synthesis, proliferation, and migration in human vascular smooth muscle cells grown from saphenous vein. TSP-1 (0.1 to 30 micrograms/mL) elicited a concentration-dependent increase in DNA synthesis under serum-free conditions. In combination with platelet-derived growth factor, TSP-1 induced a synergistic effect on DNA synthesis that was significantly higher than the additive effect of both agents. In proliferation assays, TSP-1 increased cell numbers by 50% relative to the serum-free controls over 14 days. In migration assays, conducted using modified Boyden chambers, TSP-1 (> or = 10 micrograms/mL) elicited marked chemotaxis to a degree equivalent to platelet-derived growth factor. The chemotactic response to TSP-1 (10 micrograms/mL) was abolished by the GRGDSP peptide but unaffected by the control GRGESP peptide, whereas neither peptide inhibited DNA synthesis stimulated by TSP-1. Inhibition of tyrosine kinase activity with genistein or tyrphostin A23 abolished DNA synthesis induced by TSP-1, and a neutralizing antibody to platelet-derived growth factor had no effect on DNA synthesis. Similarly, migration in response to TSP-1 was largely inhibited by these tyrosine kinase inhibitors. TSP-1 is a strong mitogen and chemoattractant for human vascular smooth muscle cells under serum-free conditions. The novel finding that TSP-1 is mitogenic for human cells contrasts with previous studies that have not shown any significant effect of TSP-1 itself on the growth of animal-derived smooth muscle cells. TSP-1 may play an important modulatory role in the local regulation of vascular smooth muscle function in vascular pathologies in humans.


Subject(s)
Chemotactic Factors/pharmacology , Mitogens/pharmacology , Muscle, Smooth, Vascular/drug effects , Thrombospondins/pharmacology , Cell Division , Cell Movement/drug effects , Cells, Cultured , DNA/biosynthesis , Humans , Muscle, Smooth, Vascular/cytology , Platelet-Derived Growth Factor/physiology , Transforming Growth Factor beta/pharmacology
10.
Arterioscler Thromb Vasc Biol ; 19(9): 2133-40, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10479655

ABSTRACT

Thrombospondin-1 (TSP-1) is a matricellular protein that is expressed in negligible amounts in normal blood vessels but is markedly upregulated in vascular injury. Although TSP-1 can act as a pleiotropic regulator for human vascular smooth muscle cells (HVSMCs), the intracellular signaling pathways stimulated by this protein remain obscure. In cultured HVSMCs derived from saphenous vein, TSP-1 induces tyrosine phosphorylation of a number of cellular proteins, with a complex temporal pattern of activation. Immunoprecipitation techniques have identified the early tyrosine-phosphorylated signals as being the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-K) and focal adhesion kinase (FAK). Tyrosine phosphorylation of the p85 subunit of PI 3-K showed a biphasic response to TSP-1 stimulation, which corresponded to a biphasic activation of the lipid kinase. Treatment with both wortmannin and LY294002 inhibited PI 3-K activity of HVSMCs but did not affect tyrosine phosphorylation of the p85 regulatory subunit. TSP-1-stimulated FAK phosphorylation, however, was substantially reduced by these inhibitors, as was the TSP-1-induced chemotaxis of these cells. These results suggest that activation of PI 3-K is an early signal induced by TSP-1 and is critical for chemotaxis. Activation of this kinase precedes and may occur upstream from FAK phosphorylation, although the nature of the interaction between these 2 enzymes remains obscure.


Subject(s)
Cell Adhesion Molecules/metabolism , Growth Substances/pharmacology , Muscle, Smooth, Vascular/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Signal Transduction/physiology , Thrombospondin 1/pharmacology , Androstadienes/pharmacology , Cells, Cultured , Chemotaxis/drug effects , Chromones/pharmacology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Focal Adhesion Kinase 1 , Focal Adhesion Protein-Tyrosine Kinases , Humans , Isoenzymes/metabolism , Morpholines/pharmacology , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Phosphoinositide-3 Kinase Inhibitors , Phosphorylation/drug effects , Protein-Tyrosine Kinases/antagonists & inhibitors , Tyrosine/metabolism , Wortmannin
11.
Pflugers Arch ; 436(1): 155-8, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9560460

ABSTRACT

Rat models of cardiac hypertrophy are characterised by a shift in left ventricular myosin isoform from V1 (adult) to V3 (foetal), the latter being associated with a slowing of the acto-myosin ATPase rate. The aim of this study was to examine hypertrophy effects on relaxation by investigating a chemically skinned cardiac preparation from the SHR, where all the cellular membranes are rendered non-functional allowing the myofibrils to be studied in isolation. On comparison, following photolysis of the photolabile caged Ca2+ chelator diazo-2, it can be seen that the SHR fibres relax at a slower rate than their age-matched WKY counterparts. We suggest that, since the thin filament regulatory proteins seem not to be affected by cardiac hypertrophy in the rat, this result can be attributed to the shift in left ventricular myosin isoforms. The reduced relaxation rate in the SHR could be the result of a slowing of the dissociation of actin and myosin during the cross-bridge cycle. These results have previously been published in abstract form [1].


Subject(s)
Chelating Agents , Hypertension/physiopathology , Hypertrophy, Left Ventricular/physiopathology , Myocardial Contraction , Actins/metabolism , Animals , Calcium/pharmacology , Diazonium Compounds , Lasers , Myosins/metabolism , Phenoxyacetates , Photolysis , Rats , Rats, Inbred SHR , Rats, Inbred WKY
SELECTION OF CITATIONS
SEARCH DETAIL